NovoCure (NVCR) Net Equity Issued and Repurchased (2014 - 2026)

NovoCure (NVCR) has reported Net Equity Issued and Repurchased for 13 consecutive years, with $2.1 million the latest figure, recorded in Q2 2026.

• Quarterly Net Equity Issued and Repurchased fell 2.01% year-over-year to $2.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.6 million (down 11.86% YoY) and the FY2025 annual result came in at $3.7 million, down 11.9% from the prior year.
• Net Equity Issued and Repurchased advanced to $2.1 million in Q2 2026 per NVCR's latest filing, from $1.5 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for NVCR reached as high as $2.9 million in Q2 2023 and fell as low as $1.5 million in Q4 2025.
• A 5-year average of $2.2 million and a median of $2.1 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased plunged 37.81% — and 2024, when it increased 28.05%.
• Year by year, Net Equity Issued and Repurchased stood at $2.5 million in 2022, then sank by 37.81% to $1.5 million in 2023, then advanced by 28.05% to $2.0 million in 2024, then declined by 22.57% to $1.5 million in 2025, then surged by 37.7% to $2.1 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $2.1 million, $1.5 million, and $2.1 million for Q2 2026, Q4 2025, and Q2 2025 respectively.